|Bid||11.25 x 1000|
|Ask||11.97 x 1100|
|Day's Range||11.21 - 11.93|
|52 Week Range||6.20 - 21.50|
|Beta (5Y Monthly)||1.83|
|PE Ratio (TTM)||8.66|
|Earnings Date||Nov 18, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Both companies I'll discuss today have reasonable valuations, and more importantly, they make products that the healthcare system can't do without. If you were recently vaccinated against the coronavirus, Retractable Technologies (NYSEMKT: RVP) might have helped. The company's retractable needles and syringes are perfect for mass vaccination campaigns thanks to their ergonomic design, which also has improved safety features to protect caregivers from injury.
LITTLE ELM, Texas, August 17, 2021--Retractable Technologies, Inc. (NYSE American: RVP) reports that its operating income was $36.1 million for the first six months of 2021, compared to an operating income for the same period last year of $1.4 million, and that income applicable to common shareholders was $28.5 million for the first six months of 2021 compared to $3.7 million in the prior year. Net sales were $42.5 million for the three months ended June 30, 2021 and $92.6 million for the six mo
Growth stocks might grab headlines and excite the market, but sometimes they end up deflating just as quickly as they climbed. In contrast, value stocks are perfect for cautious investors because they tend to have business models that have stood the test of time. Since the start of the pandemic, Retractable Technologies (NYSEMKT: RVP) has been on a tear.